PREDICTIVE AND PROGNOSTIC ROLE OF PD-L1 IN UROTHELIAL CARCINOMA PATIENTS WITH ANTI-PD-1/PD-L1 THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

被引：0
|
作者：
Tang, Kun
Jiang, Kehua
Zhou, Hui
Liu, Haoran
Ye, Zhangqun
Xu, Hua
机构：
来源：
JOURNAL OF UROLOGY | 2018年 / 199卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP78-09
引用
收藏
页码：E1040 / E1040
页数：1
相关论文
共 50 条
  • [21] The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
    Chen, Ke
    Wang, Xiao
    Yang, Liu
    Chen, Zheling
    CANCER CONTROL, 2021, 28
  • [22] Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis
    Rui, Xin
    Gu, Ting-Ting
    Pan, Hua-Feng
    Zhang, Hui-Zhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 67 : 378 - 385
  • [23] Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis
    Han Li
    Jinsheng Xu
    Yaling Bai
    Shenglei Zhang
    Meijuan Cheng
    Jingjing Jin
    Investigational New Drugs, 2021, 39 : 860 - 870
  • [24] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
    Sui, Xinbing
    Ma, Junhong
    Han, Weidong
    Wang, Xian
    Fang, Yong
    Li, Da
    Pan, Hongming
    Zhang, Li
    ONCOTARGET, 2015, 6 (23) : 19393 - 19404
  • [25] Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis
    Li, Han
    Xu, Jinsheng
    Bai, Yaling
    Zhang, Shenglei
    Cheng, Meijuan
    Jin, Jingjing
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (03) : 860 - 870
  • [26] Meta-Analysis of Anti-PD-1/PD-L1 Therapy Related Adverse Events in Clinical Trials
    Wang, Y.
    Wang, X.
    Yang, F.
    Guan, X.
    Duma, N.
    Aguilera, J. Vera
    Nowakowski, S.
    Chintakuntlawar, A. V.
    Price, A.
    Molina, J. R.
    Halfdanarson, T. R.
    Grothey, A.
    Markovic, S. N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Anti-PD-1/PD-L1 therapy for renal cell carcinoma: challenges in the development of predictive biomarkers
    Kato, Renpei
    Obara, Wataru
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (07) : 667 - 669
  • [28] Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
    Ma, Long
    Jin, Gang
    Yao, Keying
    Yang, Yi
    Chang, Ruitong
    Wang, Wenhao
    Liu, Jiawei
    Zhu, Zijiang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [29] Prognostic role of PD-L1 expression in patients with salivary gland carcinoma: A systematic review and meta-analysis
    Wu, Limeng
    Jiang, Canhua
    Zhu, Zhihui
    Sun, Yao
    Zhang, Tao
    PLOS ONE, 2022, 17 (07):
  • [30] Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
    Mishra, Surbhi
    Amatya, Sajeen Bahadur
    Salmi, Sonja
    Koivukangas, Vesa
    Karihtala, Peeter
    Reunanen, Justus
    CANCERS, 2022, 14 (20)
12345